Dicerna Pharmaceuticals, Inc. (DRNA)
(Delayed Data from NSDQ)
$13.09 USD
+0.43 (3.40%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.09 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$13.09 USD
+0.43 (3.40%)
Updated May 3, 2019 04:00 PM ET
After-Market: $13.09 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
AVEO Pharmaceuticals (AVEO) Q2 Earnings: What's in Store?
by Zacks Equity Research
On AVEO Pharmaceuticals' (AVEO) second-quarter 2018 conference call, investors' focus will remain on the company's progress with its drug Fotivda for the first-line treatment of RCC.
What's in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
On Adverum's (ADVM) second-quarter 2018 conference call, investor focus will be on the company's progress with its pipeline candidates.
Dicerna Pharmaceuticals (DRNA) in Focus: Stock Moves 6.2% Higher
by Zacks Equity Research
Dicerna Pharmaceuticals (DRNA) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
4 Sell-Ranked Drug Stocks Investors Should Avoid Ahead of Earnings
by Arpita Dutt
Here is a look at four Sell-Ranked drug stocks with negative earnings ESP that should be avoided ahead of earnings.
Can The Uptrend Continue for Dicerna Pharmaceuticals (DRNA)?
by Zacks Equity Research
Investors certainly have to be happy with Dicerna Pharmaceuticals, Inc. (DRNA) and its short term performance
Dicerna Pharmaceuticals (DRNA) Rises: Stock Climbs 14%
by Zacks Equity Research
Dicerna Pharmaceuticals, Inc. (DRNA) shares rose over 14% in the last trading session.
Cerner's EHR Platform to Enhance Health Care at San Juan NGO
by Zacks Equity Research
Cerner Corporation (CERN) announced that it recently entered into an agreement to provide San Juan Regional Medical Center with a new electronic health record platform.
Stocks Most Likely to Beat Earnings for the week of February 13th
by Zacks Equity Research
Here are four Zacks Rank #1 (Strong Buy) stocks that are likely to beat earnings for the week of February 13th:
Kindred Biosciences (KIN) Looks Good: Stock Jumps 9.5%
by Zacks Equity Research
Kindred Biosciences, Inc. (KIN) shares rose over 9% in the last trading session.
Array BioPharma (ARRY) Jumps: Stock Adds 7.5% in Session
by Zacks Equity Research
Array BioPharma Inc. (ARRY) shares rose over 7% in the last trading session.